Cover Image
Market Research Report

Global Infectious Disease Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 762834
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Infectious Disease Therapeutics Market 2019-2023
Published: December 12, 2018 Content info: 120 Pages
Description

About this market

Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. Technavio's analysts have predicted that the infectious disease therapeutics market will register a CAGR of over 4% by 2023.

Market Overview

Increasing prevalence of infectious diseases

There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.

Availability of counterfeit drugs

Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.

For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30461

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Antiviral - Market size and forecast 2018-2023
  • Antibacterial - Market size and forecast 2018-2023
  • Antifungal - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Phase III pipeline drugs for infectious diseases
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Antiviral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Antiviral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Antibacterial - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Antibacterial - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Antifungal - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Antifungal - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by type
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2018-2023 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Decision framework
  • Exhibit 42: Pipeline drugs for infectious diseases
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: AbbVie - Vendor overview
  • Exhibit 50: AbbVie - Business segments
  • Exhibit 51: AbbVie - Organizational developments
  • Exhibit 52: AbbVie - Geographic focus
  • Exhibit 53: AbbVie - Key offerings
  • Exhibit 54: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 55: F. Hoffmann-La Roche - Business segments
  • Exhibit 56: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 57: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 58: F. Hoffmann-La Roche - Segment focus
  • Exhibit 59: F. Hoffmann-La Roche - Key offerings
  • Exhibit 60: Gilead - Vendor overview
  • Exhibit 61: Gilead - Business segments
  • Exhibit 62: Gilead - Organizational developments
  • Exhibit 63: Gilead - Geographic focus
  • Exhibit 64: Gilead - Segment focus
  • Exhibit 65: Gilead - Key offerings
  • Exhibit 66: Merck - Vendor overview
  • Exhibit 67: Merck - Business segments
  • Exhibit 68: Merck - Organizational developments
  • Exhibit 69: Merck - Geographic focus
  • Exhibit 70: Merck - Segment focus
  • Exhibit 71: Merck - Key offerings
  • Exhibit 72: Sanofi - Vendor overview
  • Exhibit 73: Sanofi - Business segments
  • Exhibit 74: Sanofi - Organizational developments
  • Exhibit 75: Sanofi - Geographic focus
  • Exhibit 76: Sanofi - Segment focus
  • Exhibit 77: Sanofi - Key offerings
  • Exhibit 78: Validation techniques employed for market sizing
  • Exhibit 79: List of abbreviations
Back to Top